Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + midazolam
- Development stage
- Phase 1
- Lead developer
- Skagen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Intranasal, Intramuscular, Subcutaneous, Rectal (midazolam), Intravenous (brentuximab Vedotin)
01
Overview
**Brentuximab vedotin + midazolam** is a combination of two drugs: brentuximab vedotin, a CD30-directed antibody-drug conjugate used as an anti-neoplastic agent in various lymphomas, and midazolam, a short-acting benzodiazepine used for sedation, anxiolysis, amnesia, and treatment of seizures. Brentuximab vedotin consists of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE); it targets and releases MMAE inside CD30-positive tumor cells, causing cytotoxicity. Midazolam acts as a positive allosteric modulator at the GABA-A receptor, enhancing inhibitory neurotransmission in the brain, which leads to sedation, anxiolysis, anticonvulsant, and amnestic effects. There is no unique clinical indication for the combination; instead, clinical studies show that brentuximab vedotin does not affect midazolam pharmacokinetics, and the combination may be of interest in studying drug-drug interactions during cancer treatment[3][5].
- Brand names
- BuccolamBusulfex
- Other names
- brentuximab vedotin + midazolambrentuximab vedotinmidazolam
02
Targets
CD30 (CD30 antigen)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on brentuximab vedotin + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + midazolam.